Home Pharma China Web Edition Pharma China Archives Online Databases Subscription/Order/Info Event Calendar China Pharma Providers About Us
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Featured News
Editorials
Commentaries
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor´s Picks
 
 
 
Out of the Blue, CFDA Makes Giant Steps Forward to Boost Drug Innovation and IP ...
Chief Editor James Shen offers his monthly review of the Chinese healthcare sector with this issue's emphasis on CFDA's latest move to support drug innovation, especially... (6/5/2017)
   
China's New Cybersecurity Law And Draft Data Localization Measures Expected To Burden Multinational Companies (6/22/2017)
CFDA's New Draft Policy Introduces the Chinese Version of Patent Linkage (6/15/2017)
APAC Is the Fastest Growing Market for CRO Industry (6/15/2017)
Alzheimer's Is China's Biggest Future Health Problem - And Biggest Healthcare Industry Opportunity (6/6/2017)
ASIA: Preferred Destination for Clinical Trials (6/6/2017)
Why Europe Is Resorting to China for Its Penicillin Supply (6/5/2017)
Out of the Blue, CFDA Makes Giant Steps Forward to Boost Drug Innovation and IP Protection (6/5/2017)
NYT: China's Ill, and Wealthy, Look Abroad for Medical Treatment (5/30/2017)
Three Supreme Court Cases On Pharmaceutical Patents in China (5/25/2017)
Merck's Gardasil Preps for Head-To-Head with GSK’s Cervarix in China, With Big Sales Targets Ahead (5/24/2017)
For Millions of Chinese with Rare Diseases, Some Relief in Sight (5/19/2017) (free)
China's FDA Aims to Speed Drug OKs with Shift To U.S.-Style Clinical Trial Application Process (5/18/2017)
Winning in China's HCV Travails (5/17/2017)
Big Pharma Hopes Rule Change Will Ease China Sales Pain (5/16/2017)
From Imitator to Innovator (5/5/2017)
Recent Executive Moves  (6/22/2017)
Chi-Med Initiates a Phase I/II Clinical ...  (6/22/2017)
China's Innovative Medical Withdraws fro...  (6/22/2017)
Another Chinese API Producer in Data Int...  (6/22/2017)
Chinese Development Zone and Pakistani U...  (6/21/2017) (free)
White House Task Force Echoes Pharma Pro...  (6/21/2017)
Central Government to Support More than ...  (6/21/2017)
Analysis: New Product Additions of 2017 ...  (6/20/2017)
Snapshot: Bayer's Urban Hospital Drug Sa...  (6/20/2017)
CDE Publicizes Batch 20 of Drug Applicat...  (6/20/2017)
China Establishes National Center for Ch...  (6/20/2017)
Sanofi to e-Market Consumer Healthcare P...  (6/20/2017)
ShangPharma Announces Second Milestone i...  (6/20/2017) (free)
CFDA Announces Officially Joining the IC...  (6/19/2017)
CFDA Entrusts CPIA to Solicit Comments o...  (6/16/2017)
White House Task Force Echoes Pharma Proposals
Pharma Industry Reputation Rebounds Somewhat in 2016
Fresenius Steps Up Pharma M&A with Akorn, Merck ...
Global Pharmerging Market to Grow at a CAGR of 12.88% in...
PhRMA Urges USTR to Protect US Innovation Abroad
Analysis: New Product Additions of 2017 NRDL
Snapshot of Drug Sales of Representative Hospitals in Shanghai ...
Snapshot of Anti-hypertensive Drug Sales in Hospitals of Major ...
QuintilesIMS: Review of Chinese Pharmaceutical Market in 2016
Sinohealth: Top 20 Western Medicines by Retail Terminal Sales
China's Innovative Medical Withdraws from Investment Deal wi...
Chinese Development Zone and Pakistani University Sign MOU f...
Snapshot: Bayer's Urban Hospital Drug Sales Witness 10% Grow...
Sanofi to e-Market Consumer Healthcare Products to the Chine...
ShangPharma Announces Second Milestone in Move for Chinese S...
CDE Publicizes Batch 20 of Drug Applications To Be Grant...
CFDA Announces Officially Joining the ICH
CFDA Entrusts CPIA to Solicit Comments on Draft Provisio...
China Cracks CNY 400M Pharmaceutical Invoice Fraud Case
CFDA Releases List of Reference Formulations for Generic...
DSM Sinochem Wins Indian Patent Lawsuit against Sinopharm We...
I-MAK Challenges Gilead's Remaining Patents of HCV Drug Sofo...
China, India Named and Shamed by USTR on Lax IP
PhRMA Criticizes China Over Failure to Uphold Data Exclusivi...
China to Introduce Interpretations for Application of Crimin...
Another Chinese API Producer in Data Integrity Mudpool a...
U.S. FDA Warns Chinese API Producer for Absence of Writt...
India to Make Key APIs to Reduce Dependence on China
DSM Sinochem Pharmaceuticals Boosts Manufacturing Capaci...
U.S. FDA Raises Concerns over Teva's Plant In China
Chi-Med Initiates a Phase I/II Clinical Trial of Novel F...
BeiGene Presents Phase 1 Data on BTK Inhibitor BGB-3111 ...
Six Agencies Issue Joint Special 13th FYP for Healthcare...
China Investigates Claims of Academic Fraud Relating to ...
Chi-Med Files Chinese NDA for Anticancer Fruquintinib
Central Government to Support More than 600 Healthcare I...
China Establishes National Center for Children's Health
Anhui Slashes BMI Payment Prices of Drug Products
Number of Private Hospitals Rising But Still Insignifica...
NHFPC, SATCM Issue Joint Document to Crackdown on Health...
Recent Executive Moves
Recent Executive Moves
Recent CFDA Senior Official Moves
Recent Executive Moves
Recent Executive Moves
Upcoming Event: Biopharma Development & Producti...
Upcoming Event: 4th Annual PharmaCon Asia
Upcoming Event: ISPE Conference and Exhibition 2017
Upcoming Event: International Pharma Regulatory Summit
Upcoming Event: Risk Management in Clinical Practice: To...
Pharma China is the most influential English media and source of business intelligence covering the Chinese pharmaceutical and biopharmaceutical sector...
WiCON has been helping international healthcare companies succeed in China and other Asian markets since 1991. We advise our clients on every stage of their China and Asian business. We worked with clients in many regions of the world...
  WiCON Officially Publishes Chi...
  WiCON Officially Publishes Chi...
  WiCON and PharmaGuys Launch Ph...
  WiCON Officially Publishes Chi...
  WiCON Officially Publishes Its...
© Wicon International Group  Support by: www.heightow.com Site map | Contact Us | Links